Three Lakes Foundation and the American College of Chest Physicians (CHEST) recently announced their collaboration on a multiphase educational initiative aiming to reduce the time it takes to diagnose patients with Interstitial Lung Diseases (ILD).
Boehringer Ingelheim announced the company’s intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.
A federal judge in Delaware tossed out a lawsuit by Roche company Genentech accusing Novartis’ Sandoz division of patent infringement. In this case, the patent was related to Genentech’s Esbriet (pirfenidone), which is used to treat idiopathic pulmonary fibrosis.
Hong Kong-based Insilico Medicine closed on a Series C financing round worth $255 million.
Across the pharmaceutical industry, forging collaborations are a key tool to bringing new medications through the clinic and to market. This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace took a look at some of these announcements.
Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.
Glympse Bio secured $46.7 million in a Series B fundraising round that will be used to support continued development of the company’s novel biosensor platform in fibrotic diseases such as non-alcoholic steatohepatitis (NASH), oncology and infectious diseases.
Veracyte Inc. and Yale University announced an exclusive licensing agreement to advance the first genomic test for predicting disease progression in patients with idiopathic pulmonary fibrosis (IPF).
With a busy week for biotech quarterly and annual reports, here is a look at some of the top stories.
Drug development accelerator BioMotiv and Bristol-Myers Squibb jointly launched Anteros Pharmaceuticals, which will focus on developing a new class of medicines for fibrotic and inflammatory diseases.
